Metastatic disease accounts for over 90% of cancer-related deaths, but the development of effective anti-metastatic agents has been hampered by the paucity of clinically relevant preclinical models of human metastatic disease. 
Introduction
Metastasis formation is a complex and dynamic process in which cancer cells escape the primary tumor and disseminate to secondary organs by successfully advancing through a sequence of several steps. After initial invasion of the extracellular matrix, cancer cells intravasate into blood and lymphatic vasculature, survive during transit and extravasate to colonize distant organs (1) (2) (3) .
Despite recent advances, many of the mechanisms by which cancer cells acquire the ability to overcome each of these successive barriers remain poorly understood. Furthermore, a growing body of evidence indicates that metastasis formation is influenced by a continuous cross-talk between cancer cells and their stromal environment (4) . For example, organ-specific patterns of metastatic spread observed in distinct (sub)types of cancer strongly suggest that host factors play a critical role in the dissemination of cancer cells (5) . This notion is further supported by the observation of chemokine-mediated trafficking of circulating tumor cells to distant sites (6) . Recent studies also suggest that tumor-derived factors can facilitate metastatic colonization by recruiting bone marrow-derived hematopoietic progenitor cells to secondary sites, where these cells prime their environment to form a more hospitable and survival-permissive pre-metastatic niche (7) (8) (9) .
To study metastasis formation in vivo, several mouse models of metastatic disease have been developed. Unfortunately, most of the currently available models only partially reflect the metastatic cascade. For example, experimental metastasis models based on intravenous injection of cancer cells do not recapitulate tumor cell invasion and intravasation, but only reflect homing of circulating tumor cells to an often limited set of secondary organs (10; 11) . These issues are partially resolved in syngeneic or xenograft tumor transplantation models in which tumor cells derived from an established cancer cell line are transplanted subcutaneously or orthotopically into recipient mice. Xenograft metastasis models which carefully reflect cancer-cell intrinsic traits of parental human carcinomas are easily manipulated for mechanistic studies and have been particularly useful to evaluate therapeutic compounds targeting metastatic disease (12) . However, in vitro maintained cancer cell lines fail to retain the cellular heterogeneity originally found in the parental tumor (13) . Therefore, phenotypic variations in metastatic capacity that are present in spontaneous tumors are generally not recapitulated in cancer cell line-based metastasis models.
Furthermore, xenograft metastasis models cannot be used to study the role of the adaptive immune system in disease progression and metastasis formation.
A third alternative to study metastasis formation in vivo is the employment of mouse models of de novo tumorigenesis. Utilizing these spontaneous mouse models to study metastatic dissemination offers several advantages over the previously described experimental systems (11) .
First, tumors derived from genetically engineered mouse (GEM) models often closely recapitulate the histopathological characteristics observed in human cancer. Furthermore, tissue-specific induction of mutations gives rise to orthotopic tumors in the context of a functional, immune competent microenvironment, thus recapitulating the cross-talk between an emerging tumor and its surroundings. Consequently, mouse models of de novo tumorigenesis are useful to study early stages of metastatic spread and to explore the role of the stromal microenvironment in disease progression. Nonetheless, studying advanced metastatic disease in GEM models is often hampered by the relatively low incidence of metastatic disease. Even if metastatic dissemination occurs, most animals will -unlike in human cancer -die from rapidly growing primary tumors that do not allow sufficient time for the emergence of advanced, clinically overt metastatic disease. Though these issues could be resolved by surgical resection of the primary tumor, this often proves unpractical as most animals develop multiple, asynchronously arising primary tumors (12 
Materials and Methods

Mice
The generation and characterization of K14cre;Cdh1 F/F ;Trp53 F/F mice -back-crossed onto the FVB/N background for this study -has previously been described in detail (14) . Genotyping was performed by PCR analysis on tail tip DNA as described previously (14) . Female FBV/N mice (aged 10-12 weeks) were bred at and obtained from the laboratory animal facility at the Netherlands Cancer Institute. Mice were kept in individually ventilated (intervention studies) and open cages (all other experiments) and food and water were provided ad libitum. Mouse handling and animal experimental procedures were approved by the institute's Animal Ethics Committee and were performed in accordance with institutional guidelines and national ethical regulations.
Isolation of mammary donor tumors
In K14cre;Cdh1 F/F ;Trp53 F/F females, the onset of mammary tumor formation was monitored twice weekly by palpation starting at 4 months of age. Mammary tumor growth was measured using calipers. Once mammary tumors reached a size of ~10x10 mm, tumors were harvested and cut in small pieces (diameter ~1mm) while submerged in ice-cold PBS. Tumor fragments were collected by centrifugation at 1200 rpm for 5 min, resuspended in DMEM F12 containing 30% fetal calf serum and 10% dimethyl sulfoxide and stored at -150 °C till further use.
Orthotopic tumor transplantations
Based on immunohistochemical stainings, three K14cre;Cdh1 F/F ;Trp53 F/F derived mouse invasive lobular carcinomas (mILCs) -characterized by high cytokeratin 8 and absence of vimentin and Ecadherin expression -isolated from three independent mice were selected and used as donor tumors. Small tumor fragments (~ 1 mm in diameter) from these donor mILCs were orthotopically transplanted into the mammary fat pad of 10 week old wild-type syngeneic female recipients as described previously (15) . Briefly, recipient animals were anesthetized by injecting a 7 ml/kg bolus of a 1:1:2 mixture of Hypnorm (Janssen Pharmaceutica, Goirle, The Netherlands) : Dormicum (Roche) : ddH2O intraperitoneally. After shaving and disinfection, a midline abdominal incision of 1cm was made at the level of the 4 th nipple and a small pocket was created by puncturing the mammary fat pad using watchmaker's forceps. A tumor fragment was inserted distal to the local lymph node, the mammary gland was repositioned, skin was stitched and buprenorfine 100 μg/kg was administered subcutaneously for postoperative pain relief.
The first occasion at which a tumor mass of ~ 2x2 mm was identified, was defined as the time of diagnosis. Tumor growth was measured twice weekly using calipers. Once recipient mammary tumors reached a size of ~ 15x15 mm, a mastectomy was performed. After induction of anesthesia and disinfection, a 2cm midline abdominal skin incision was made and tumor-supplying arteries were located and ligated. The mammary tumor including adjacent 4 th and 5 th mammary glands were separated from adherent tissues using forceps and soaked cotton swabs and the mammary tumor was excised and stored for further analysis. The skin was closed using stitches and buprenorfine 100 μg/kg was given for postoperative analgesia.
Monitoring of metastatic disease
Following mastectomy, all mice were monitored for disease progression and metastasis formation 
Histopathological and genomic characterization of mammary tumors and metastases
Mammary tumors and metastases were characterized by histopathological, immunohistochemical and array comparative genomic hybridization (aCGH) analyses. Detailed methods are described in supplementary material.
Neo-adjuvant and adjuvant chemotherapy treatments
To study chemotherapy responses in mammary tumors and distant metastases, we generated a cohort of recipient mice transplanted with the same donor tumor (donor tumor 1). Tumor-bearing recipients were assigned to adjuvant or neo-adjuvant treatments with PBS (control), doxorubicin (5mg.kg Following mastectomy at a tumor size of ~15x15mm, neo-adjuvant treated mice were monitored for disease progression as described previously. Adjuvant treated recipients underwent a mastectomy once the mammary tumor reached a size of 15x15 mm. Adjuvant treatments were initiated three days after mastectomy according to the same treatment schedule. Therapeutic profiles of mammary tumors and distant metastases were studied using mammary tumor growth (neo-adjuvant setting only) and metastasis-specific survival (both settings) as primary endpoints.
Statistical analysis
Array CGH data analyses were performed in R using the comparative module of the Kcsmart (16; 17) as implemented in the Bioconductor toolbox (version 2. 
Surgical resection of mammary tumors results in widespread clinically overt metastatic disease in recipient mice
To examine whether transplanted recipient mILCs maintain their capacity to disseminate and establish spontaneous metastases, we surgically resected recipient mammary tumors at a size of ~ 15x15 mm (Fig. 1A) . Following mastectomy, 32/44 recipient mice succumbed to clinically overt metastatic disease in lungs (respiratory distress), liver (severe anemia, ascites accompanied by weight gain and a distended abdomen), spleen (palpable tumor mass) and/or tumor-draining or distant lymph nodes (tumor mass reaching a size of ~15x15 mm) (Fig. 3A) . In addition, 12/44 recipient mice died due to locally relapsing tumors (Fig. 3A) .
To further assess the extent and distribution of metastatic spread in our model, we microscopically analyzed organs isolated from recipient mice for the presence of metastatic foci. In 40/44 recipient mice, we observed metastatic foci in at least one organ. In 30/44 recipients, two or more organs were affected by metastatic disease (Fig. 3B) . Consistent with our clinical findings, metastases were predominantly observed in lungs and tumor-draining lymph nodes, though liver, spleen and distant lymph nodes were also frequently affected (Table 1 and Fig. 3C ). Furthermore, metastatic lesions were also observed in pancreas, mesenterium and peritoneum. This pattern of metastatic spread strongly correlates with the spectrum of organs affected in human ILC, as human ILCs are prone to metastasize to gastro-intestinal tract, ovaries and peritoneum (18) . Together, these data show that recipient mILCs vigorously metastasize leading to widespread, clinically overt metastatic disease in a variety of organs.
Metastatic dissemination occurs spontaneously and is not instigated by surgical manipulation of the primary tumor
We aimed for a model in which metastatic dissemination occurs spontaneously. Yet, we could not exclude the possibility that metastatic disease in our model was inadvertently initiated by shedding cancer cells during surgical manipulation of the primary tumor. We reasoned that if metastatic dissemination was exclusively initiated by surgery-induced shedding of cancer cells, the occurrence of metastatic disease would be determined by the time of mastectomy. As a consequence, metastasis-specific survival after surgery would be similar for mice that undergo surgery at different time points in tumor development. Furthermore, surgery-induced shedding of cancer cells would be independent of the size of the resected primary tumor. To test these hypotheses, we performed a mastectomy at different time points during tumor development and surgically resected recipient tumors that reached a size of 5x5, 10x10 or 15x15 mm (Fig. 4A ).
Surgical resection of mammary tumors at a size of ≥10x10 mm led to metastatic disease in all animals, whereas mastectomy at a tumor size of 5x5 mm led to metastatic disease in only 55% of the animals (Fig. 4B) . Interestingly, irrespective of the size of a resected tumor and the time of surgery, the interval between diagnosis of the primary tumor and the occurrence of clinically overt metastatic disease remained similar for mice that succumbed to metastatic disease (Fig. 4B ). These data suggest that metastatic dissemination occurs around the time that a primary tumor reaches a size of ~5x5mm. To ensure that metastatic dissemination was not inadvertently initiated by shedding cancer cells during surgery, we reanalyzed these data and focused on the interval between surgery and the occurrence of metastatic disease. Metastasis-specific survival after surgery was inversely related to the time of surgery and the size of a resected tumor (Fig. 4C) . Thus, these data suggest that metastatic dissemination in our model occurs spontaneously and is not initiated by surgery-induced shedding of cancer cells. However, these data do not exclude the possibility that surgical manipulation of the primary tumor contributes to metastatic dissemination of cancer cells. To explore the relationship between recipient mammary tumors and their distant metastases, we characterized metastases by morphological, immunohistochemical and aCGH analyses and compared them to the parental recipient tumor. Metastatic foci were morphologically similar to epithelial regions within the corresponding recipient mammary tumor and expressed CK8, but not vimentin nor E-cadherin (Fig. 5A) . These findings suggest that metastatic foci are either exclusively seeded by epithelial-like cancer cells or that both epithelial and mesenchymal-like cancer cells metastasize and eventually remain or transform to epithelial cells by a process known as mesenchymal-to-epithelial transition. Similar to parental recipient tumors, metastatic foci also showed abundant immune cell infiltrations (Fig. 5B) .
To investigate the genomic relationship between recipient mammary tumors and their metastases, we performed aCGH and analyzed genomic profiles of paired primary tumors and distant metastases (Fig. S3) . Unsupervised hierarchical clustering of genomic profiles revealed that local tumors and their distant metastases cluster according to the parental donor tumor (Fig. 5C ).
Within these clusters, neither recipient mammary tumors and their corresponding metastases nor site-specific lesions (i.e. mammary tumors, lymph node and lung metastases) could be separated (Fig. 5C) . Thus, these data show that genomic profiles of clonally-related recipient tumors are highly conserved in regional and distant metastases and that few genomic alterations occur during transition from a primary tumor to a distant site. To more thoroughly examine potential sitespecific alterations, we constructed so-called 'delta-profiles' and calculated the difference between the genomic profile of a recipient mammary tumor and its paired lymph node-or lung metastasis.
Though we detected some differences, we did not observe recurrent site-specific alterations in genomic profiles of lymph node or lung metastases (Fig S4) . Thus, these data show that recipient mammary tumors and distant metastases exhibit similar genomic profiles and that if copy number changes occurred, they did not recur in independent samples.
Mammary tumors and distant metastases exhibit similar therapeutic profiles upon (neo-)adjuvant treatment with standard-of-care chemotherapeutics
To study chemotherapy responses of clonally related mammary tumors and distant microscopic metastases, we generated a cohort of recipient mice transplanted with the same donor tumor. Tumor-bearing recipients were then assigned to adjuvant or neo-adjuvant treatments with PBS (control), doxorubicin or docetaxel. In both settings, treatments were administered once weekly for a fixed period of 4 weeks (Fig. 6A) . Neo-adjuvant treatments initiated at a tumor size of 5x5mm resulted in marked stasis in tumor development. However, tumors rapidly regained growth after completion of the treatment (Fig. 6A&B) . Consequently, neo-adjuvant treated animals that underwent a mastectomy at a tumor size of 15x15mm eventually succumbed to metastatic disease (Fig. 6C&D) . Likewise, adjuvant chemotherapy treatments targeting clinically undetectable microscopic metastases were initiated three days after mastectomy and led to an initial but temporary response resulting in a clear increase in metastasis-specific survival (Fig. 6C&D) . Consistent with observations in human invasive lobular carcinoma (22) , these data show that (neo-)adjuvant treatments with doxorubicin and docetaxel result in a survival benefit, but do not give rise to a durable, complete response. Furthermore, treatment-associated survival benefits for adjuvant and neo-adjuvant treated cohorts suggest that mammary tumors and distant metastases exhibit similar therapeutic profiles upon (neo-)adjuvant treatment with the standard-of-care chemotherapeutics doxorubicin and docetaxel.
Research. Based on these results, we believe that our model provides a valuable tool to study observed in these models (23 recipient mammary tumors in our model are more likely to reflect the heterogeneity also observed in human cancer (24; 25) . Though more realistic, it is important to note that this biological variety comes at the expense of experimental flexibility as tumors are more difficult to manipulate.
Second, by transplanting mILC fragments into syngeneic hosts, we were able to reconstitute mammary tumors in the context of a functional, immune-proficient microenvironment. Therefore, our model can be utilized to address the role of the immune system in breast cancer metastasis formation. This is essential, since accumulating evidence indicates that immune cells and their soluble mediators modulate the process of metastatic spread both at the level of the primary tumor as well as at distant sites (4; 26). Furthermore, since this system permits easy manipulation of the stromal compartment by transplanting tumor fragments into hosts with altered stromal traits, it can also be used to assess the functional involvement of other cancer-cell extrinsic factors.
Third, unlike in other models (27) , metastatic disease in our model is not confined to a limited set of distant sites, but encompasses a variety of lymphoid and visceral organs. The common involvement of tumor-draining and distant lymph nodes suggests that metastatic spread in our model occurs at least partially by spontaneous lymphatic dissemination of cancer cells. In contrast to some other models, this pattern of metastatic dissemination arises spontaneously and does not require in vivo enrichment, selection and re-injection of cancer cells. Moreover, the distribution of organs affected by metastatic disease in our model is highly reminiscent to the metastatic spectrum observed in human invasive lobular breast cancer (18) . Thus, based on these merits, our model presumably more closely reflects the biology of organ-specific metastatic colonization. Since various organs are often affected simultaneously, this model allows a careful, paired analysis of metastases arising in different anatomical locations as illustrated by our genomic studies. Extending these studies by an in-depth comparison of metastatic foci to their parental tumor paves the way to gain new insights into mechanisms regulating organ-specific metastasis formation.
Fourth, metastatic dissemination in our model led to clinically overt metastatic disease thus allowing us to determine metastasis-specific survival based on clinically defined endpoints. These clinically defined endpoints provide a more precise estimation of disease burden, as number, size and cumulative area of metastatic foci not necessarily correlate with the disturbance of organ function. For example, solely based on their critical location only few lung metastases might lead to a rapid deterioration in respiratory capacity. Likewise, pleural effusions commonly observed in lung metastases-bearing animals have a profound impact on respiratory capacity. Ultimately, these factors collectively result in organ failure leading to clinical signs of respiratory distress. As a result, 
clinical signs of metastatic disease and related metastasis-specific survival more precisely reflect the disease burden as they incorporate all the afore mentioned factors.
Finally, given its penetrant and predictive metastatic phenotype, our model can also be used as a preclinical tool to test (novel) therapeutic agents targeting metastatic disease (27) . As demonstrated by our chemotherapy intervention experiments, these studies can either be performed in an adjuvant or neo-adjuvant setting, thus allowing a careful and independent evaluation of therapeutic agents targeting the primary tumor and low-volume microscopic or advanced metastatic disease. In conclusion, we successfully developed a preclinical mouse model of de novo breast cancer metastasis formation that maintains and exploits the unique features of the original
;Trp53 F/F model, while simultaneously circumventing its limitations by performing a mastectomy to prevent premature tumor-associated loss of recipient mice. We believe that this model provides a valuable tool to study the biology of metastatic disease and to evaluate the efficacy of (novel) therapeutic agents targeting metastatic disease. Our experimental approach can be applied to similar mouse models of de novo tumorigenesis, thus yielding a broader availability of mouse models that faithfully recapitulate metastatic disease in humans. Together, these models are likely to provide new insights that will support the development of more effective treatment strategies and may therefore benefit many patients suffering from metastatic disease.
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